- Home
- ECBK vs GNLX Comparison
ECBK vs GNLX Comparison
Compare ECBK & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- GNLX
- Stock Information
- Founded
- ECBK 1919
- GNLX 2001
- Country
- ECBK United States
- GNLX United States
- Employees
- ECBK N/A
- GNLX N/A
- Industry
- ECBK Banks
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- ECBK Finance
- GNLX Health Care
- Exchange
- ECBK Nasdaq
- GNLX Nasdaq
- Market Cap
- ECBK 151.0M
- GNLX 128.0M
- IPO Year
- ECBK N/A
- GNLX 2023
- Fundamental
- Price
- ECBK $15.75
- GNLX $3.15
- Analyst Decision
- ECBK
- GNLX Strong Buy
- Analyst Count
- ECBK 0
- GNLX 5
- Target Price
- ECBK N/A
- GNLX $16.20
- AVG Volume (30 Days)
- ECBK 14.4K
- GNLX 136.2K
- Earning Date
- ECBK 07-24-2025
- GNLX 08-07-2025
- Dividend Yield
- ECBK N/A
- GNLX N/A
- EPS Growth
- ECBK 52.06
- GNLX N/A
- EPS
- ECBK 0.64
- GNLX N/A
- Revenue
- ECBK $27,795,000.00
- GNLX N/A
- Revenue This Year
- ECBK N/A
- GNLX N/A
- Revenue Next Year
- ECBK N/A
- GNLX N/A
- P/E Ratio
- ECBK $24.60
- GNLX N/A
- Revenue Growth
- ECBK 12.29
- GNLX N/A
- 52 Week Low
- ECBK $12.56
- GNLX $1.91
- 52 Week High
- ECBK $16.99
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- ECBK 47.91
- GNLX 44.93
- Support Level
- ECBK $15.33
- GNLX $3.32
- Resistance Level
- ECBK $16.13
- GNLX $3.61
- Average True Range (ATR)
- ECBK 0.38
- GNLX 0.24
- MACD
- ECBK -0.04
- GNLX -0.04
- Stochastic Oscillator
- ECBK 32.31
- GNLX 1.79
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.